Premium
Methadone—Not a magic bullet in melanoma therapy
Author(s) -
Brüggen MarieCharlotte,
Mangana Joanna,
Irmisch Anja,
French Lars E.,
Levesque Mitchell P.,
Cheng Phil F,
Dummer Reinhard
Publication year - 2018
Publication title -
experimental dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.108
H-Index - 96
eISSN - 1600-0625
pISSN - 0906-6705
DOI - 10.1111/exd.13543
Subject(s) - melanoma , viability assay , medicine , cancer research , temozolomide , chemotherapy , magic bullet , cancer , oncology , cisplatin , cell culture , pharmacology , immunology , biology , bioinformatics , genetics
Methadone (Met) mainly acts as a μ‐opioid receptor agonist. Recent evidence pointing towards the role of Met in sensitization of certain cancer cell lines to chemotherapeutic agents has promoted the hypothesis that Met may be a useful adjuvant to cancer chemotherapy. We wanted to address whether Met has, alone or in combination with a chemotherapeutic agent, an effect on melanoma cell viability in vitro. Only a small fraction (4.3%) of our 102 melanoma biobank cell lines with RNA ‐sequencing data showed expression of the main receptor for Met ( OPRM 1). We assessed the viability of melanoma cell lines with high, medium or low/no OPRM 1 expression ( OPRM 1 high , OPRM 1 med , OPRM 1 neg ) 72 hours after treatment with Met alone or combined with cisplatin (Cis). Our analyses show that Met alone did not affect cell viability. While Cis/Met treatment did not have an effect on viability of OPRM 1 med or OPRM 1 neg cell lines, it resulted in a slightly decreased cell viability of OPRM 1 high cells. Clinically, concurrent temozolomide/Met treatment did not have an effect in our single‐case report of a patient suffering from uveal melanoma. Taken together, our findings do not provide evidence for recommending Met as an adjuvant to chemotherapy in patients with melanoma.